Drug major Natco Pharma has got approval from the Drugs Controller General of India (DCGI) to sell generic version of Daclatasvir, which is used for treatment of chronic hepatitis C. Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Natco Pharma becomes the first in India to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India).

Natco said it will market generic Daclatasvir under its own brand ‘NATDAC’, and through its strategic partners in India. Natco will launch immediately in India at Rs 6,000 and Rs 4,000 for the 60 mg and 30 mg strengths, respectively, for a bottle of 28 tablets.

Hepatitis

• Hepatitis is a medical condition defined by the inflammation of the liver and characterized by the presence of inflammatory cells in the tissue of the organ.
• The most common causes of viral hepatitis are the five unrelated hepatotropic viruses hepatitis A, hepatitis B, hepatitis C, hepatitis D (which requires hepatitis B to cause disease), and hepatitis E
• Excessive alcohol consumption is a significant cause of hepatitis and liver damage (cirrhosis). Alcoholic hepatitis usually develops over years-long exposure to alcohol
• The World Health Organization recommends vaccination of all children, particularly newborns in countries where hepatitis B is common to prevent transmission from the mother to child.

World Hepatitis Day is Observed on July 28

Theme – “Prevent hepatitis. Act now”